The University of Maryland - Developmental Therapeutics Review - Q4 2010

Global Markets Direct, December 2010, Pages: 80

The University of Maryland – Developmental Therapeutics Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “The University of Maryland – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by The University of Maryland.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of The University of Maryland with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of The University of Maryland’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.

Reasons to buy

- Identify new drug targets and therapeutic classes in The University of Maryland’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate The University of Maryland’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of The University of Maryland in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with The University of Maryland.
- Avoid Intellectual Property Rights related issues.

List of Tables
List of Figures
The University of Maryland Snapshot
The University of Maryland Overview
Key Information
Key Facts
The University of Maryland – Research and Development Overview
Key Therapeutic Areas
The University of Maryland – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
The University of Maryland – Pipeline Products Glance
The University of Maryland – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
The University of Maryland Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
The University of Maryland – Drug Profiles
Quetiapine + Risperidone
Product Description
Mechanism of Action
R&D Progress
Anti-thymocyte globulin + Graft-versus-tumor induction therapy + Cyclophosphamide + Melphalan
Product Description
Mechanism of Action
R&D Progress
bevacizumab + cytarabine + mitoxantrone hydrochloride
Product Description
Mechanism of Action
R&D Progress
Budesonide + Rectal Hydrocortisone
Product Description
Mechanism of Action
R&D Progress
carmustine + cisplatin + cyclophosphamide + dexamethasone + etoposide + melphalan + paclitaxel + stem cell transplantation
Product Description
Mechanism of Action
R&D Progress
Chantix
Product Description
Mechanism of Action
R&D Progress
CVD 1208S
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Melphalan + Anti-thymocyte globulin + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
daclizumab + therapeutic allogeneic lymphocytes + mycophenolate mofetil + tacrolimus
Product Description
Mechanism of Action
R&D Progress
Erbitux + Taxol + Paraplatin + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Filgrastim + Pneumococcal Polyvalent Vaccine + Carmustine + Cyclophosphamide + Melphalan + Therapeutic Autologous Lymphocytes + Peripheral Blood Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
filgrastim + pneumococcal polyvalent vaccine + therapeutic autologous lymphocytes + therapeutic tumor infiltrating lymphocytes + carmustine + cyclophosphamide + melphalan + Stem Cell Transplantation
Product Description
Mechanism of Action
R&D Progress
filgrastim + recombinant interferon alfa + sargramostim + therapeutic autologous lymphocytes + carmustine + cyclophosphamide + etoposide + gemcitabine hydrochloride + melphalan
Product Description
Mechanism of Action
R&D Progress
gefitinib
Product Description
Mechanism of Action
R&D Progress
Genasense + Dexamethasone + Thalidomide
Product Description
Mechanism of Action
R&D Progress
pentamidine
Product Description
Mechanism of Action
R&D Progress
Vorinostat + Lapatinib
Product Description
Mechanism of Action
R&D Progress
Benzoylphenylurea for Solid Tumor
Product Description
Mechanism of Action
R&D Progress
CVD 1902
Product Description
Mechanism of Action
R&D Progress
Cyclophosphamide + Etoposide + Filgrastim + White Blood Cell Infusion
Product Description
Mechanism of Action
R&D Progress
Dendritic Cell Vaccine
Product Description
Mechanism of Action
R&D Progress
HPV-16 Vaccine + Montanide ISA 51 + GM-CSF
Product Description
Mechanism of Action
R&D Progress
KML-001 + Cisplatin
Product Description
Mechanism of Action
R&D Progress
Lamivudine + Tenofovir disoproxil + Nelfinavir
Product Description
Mechanism of Action
R&D Progress
MAGE-A3 + Montanide ISA 51 + GM-CSF
Product Description
Mechanism of Action
R&D Progress
MAGE-A3 HPV-16 Vaccine
Product Description
Mechanism of Action
R&D Progress
temozolomide + veliparib
Product Description
Mechanism of Action
R&D Progress
tributyrin
Product Description
Mechanism of Action
R&D Progress
UCN-01 + carboplatin
Product Description
Mechanism of Action
R&D Progress
The University of Maryland – Pipeline Analysis
The University of Maryland – Pipeline Products by Therapeutic Class
The University of Maryland Pipeline Products By Target
The University of Maryland – Pipeline Products by Route of Administration
The University of Maryland – Pipeline Products by Molecule Type
The University of Maryland - Dormant Projects
The University of Maryland – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Financial Deals Landscape
The University of Maryland, Deals Summary, 2004 to 2010
The University of Maryland Detailed Deal Summary
T-Solar Enters Into Joint Venture With Global EcoPower
Licensing Agreements
Horizon Discovery Enters Into Licensing Agreement With University of Maryland
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Biodefense Industry - Market to Benefit from Federal Funding such as the BIO EDEP Fund to Support Security Plans
• Education Services - Global Strategic Business Report
• Charter Schools - Global Outlook
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• International Military and Government Helicopter Survey
• Trends in Photography Special Collections Management, 2011 Edition
• Sports and Fitness Nutrition - Global Strategic Business Report
• Creating the Digital Library, 2012 Edition